Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis b and Lewis y antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
1. A method for treating necrotizing enterocolitis (NEC), the method comprising:
administering to an infant having NEC an effective amount of a composition comprising one or more alpha-1,2 fucosyl glycans,
wherein the infant is a premature infant or an infant having a birth weight of less than 2500 grams, and
wherein the one or more alpha-1,2 fucosyl glycans are either purified from a natural source or chemically synthesized.
2. The method of claim 1 , wherein the one or more alpha-1,2 fucosyl glycans each include a fucose terminus in an α1,2-linkage to a core sequence, which is Gal(β1-3)GlcNAc-R 1 or Gal(β1 -3)GlcNAc-R 2 , each of R 1 and R 2 independently being H, a small radical, a monosaccharide, a disaccharide, or a polysaccharide.
3. The method of claim 2 , wherein the one or more alpha-1,2 fucosyl glycans are selected from the group consisting of 2′-fucosyllactose (2′-FL), lacto-N-fucopentaose-I (LNF-I), lacto-N-difucohexaose I (LDFH I), and lactodifucotetraose (LDFT).
4. The method of claim 1 , wherein the one or more alpha-1,2 fucosyl glycans are conjugated to a scaffold.
5. The method of claim 4 , wherein the scaffold is a glycoprotein, a glycopeptide, a glycolipid, or a mucin.
6. The method of claim 1 , wherein the composition further comprises one or more probiotic organisms.
7. The method of claim 6 , wherein the one or more probiotic organisms are selected from the group consisting of Lactobacilli rhamnosus GG, Lactobacilli acidophilus, Lactobacilli casiei, Lactobacilli plantarum, Lactobacilli reuteri, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium Breve, Bifidobacterium animalis lactis, Bifidobacterium longum, Streptococcus thermophiles, Saccharomyces boulardii , and Kluyveromyces lactis.
8. The method of claim 1 , wherein the composition further comprises one or more prebiotics.
9. The method of claim 8 , wherein the one or more prebiotics are fructo-oligosaccharides.
10. The method of claim 9 , wherein the fructo-oligosaccharides are inulin, xylooligosaccharides, or galactooligosaccharides.
11. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
12. The method of claim 1 , wherein the composition is administered to the infant multiple times per day, once per day, or once per week.
13. The method of claim 1 , wherein the composition is administered to the infant for at least 4 weeks.
14. The method of claim 1 , wherein the composition is administered orally.
15. The method of claim 1 , wherein the composition is administered orally to the infant multiple times per day, once per day, or once per week for at least 4weeks.
16. The method of claim 1 , wherein the premature infant is an infant who is born at less than 37 weeks gestational age.
17. The method of claim 1 , wherein the infant has a birth weight of less than 1000 grams.
18. A method for treating a gastrointestinal infectious or gastrointestinal inflammatory disorder, the method comprising:
administering to an infant having a gastrointestinal infectious or gastrointestinal inflammatory disorder an effective amount of a composition comprising one or more alpha-1,2 fucosyl glycans,
wherein the infant is a premature infant or an infant having a birth weight of less than 2500grams,
wherein the one or more alpha-1,2 fucosyl glycans are either purified from a natural source or chemically synthesized, and
wherein if the infant has a gastrointestinal infectious disorder, the infant does not have diarrhea.
19. The method of claim 18 , wherein the one or more alpha-1,2 fucosyl glycans each include a fucose terminus in an α1,2-linkage to a core sequence, which is Gal(β1-3)GlcNAc-R 1 or Gal(β1-3)GlcNAc-R 2 , each of R 1 and R 2 independently being H, a small radical, a monosaccharide, a disaccharide, or a polysaccharide.
20. The method of claim 19 , wherein the one or more alpha-1,2 fucosyl glycans are selected from the group consisting of 2′-fucosyllactose (2′-FL), lacto-N-fucopentaose-I (LNF-I), lacto-N-difucohexaose I (LDFH I), and lactodifucotetraose (LDFT).
21. The method of claim 18 , wherein the composition further comprises one or more probiotic organisms.
22. The method of claim 18 , wherein the composition further comprises one or more prebiotics.
23. The method of claim 18 , wherein the premature infant is an infant who is born at less than 37 weeks gestational age.
24. The method of claim 18 , wherein the infant has a birth weight of less than 1000 grams.
25. The method of claim 18 , wherein the gastrointestinal infectious or gastrointestinal inflammatory disorder is selected from the group consisting of necrotizing enterocolitis (NEC), a gastrointestinal infection, gastrointestinal inflammation, and sepsis.
26. The method of claim 18 , wherein the infant has a gastrointestinal inflammatory disorder.